Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury

Jiri Aubrecht; Shelli J Schomaker; David E Amacher

doi:10.1186/gm489

Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury

Genome Med. 2013 Sep 27;5(9):85. doi: 10.1186/gm489. eCollection 2013.

Authors

Jiri Aubrecht¹, Shelli J Schomaker¹, David E Amacher²

Affiliations

¹ Drug Safety R&D, Pfizer Inc., Eastern Point Rd, Groton, CT, USA.
² Toxadvisor Toxicology Consulting, Hadlyme, CT, USA.

PMID: 24073687
PMCID: PMC3979132
DOI: 10.1186/gm489

Abstract

Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategies that improve the diagnosis of DILI by providing increased specificity and/or by identifying individual patients who are at risk for DILI is therefore crucial. See related Research, http://genomemedicine.com/content/5/9/86.